Biography

Dr. Liu has served as a director since January 2023. Dr. Liu has served as the Chief Executive Officer of PAX Therapeutics since 2020 and is an Adjunct Full Professor at the University of California, San Francisco and Hedersdoktor with scientific affiliation in the Department of Medicine at the Karolinska Institutet. She widely consults for companies and NGOs such as the World Health Organization through her activities as Principal of ProTherImmune LLC. She is a Board Member of the International Society for Vaccines (and President Emerita) as well as a Director of Ipsen, where she chairs the Ethics and Governance Committee and is a member of the Innovation and Development Committee, and was on the Innovation and Development Committee-Consumer Healthcare prior to the sale of that division in 2022. Dr. Liu is a member of the Supervisory Board of NanoBiotix. She served on the boards of Transgene, Sangamo Biosciences, Adjuvance Technologies, and the International Vaccine Institute (established by the United Nations Development Programme) where she was chair of the Governance Committee and had previously been chair of the Scientific Advisory Group, was Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation and earlier held positions of increasing responsibility at Merck & Co. and Chiron Corporation. Dr. Liu obtained an M.D. from Harvard Medical School and a B.A. in Chemistry summa cum laude from Colorado College. She is known as The Mother of DNA vaccines for her ground-breaking work in that technology. She completed an Internship and Residency in Internal Medicine and a Fellowship in Endocrinology, all at Massachusetts General Hospital/Harvard Medical School and received board certification in both, and was an Instructor in Medicine at Harvard University. Dr. Liu was also a Visiting Scientist at MIT, where she pioneered bispecific antibodies, an Adjunct Assistant Professor of Medicine at the University of Pennsylvania, and a member of the NIH NIAID Advisory Council. The Board believes that Dr. Liu’s medical training and more than 30 years of experience in biotechnology and pharmaceuticals qualify her to serve as a member of our Board.